Glaukos Corporation Glaukos Corporation

Glaukos Corporation

GKOS

Rang in aandelen #1965
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Aandeelprijs
$177.09
Laatst gesynchroniseerd: 2026-10-21
Marktkapitalisatie
$10.45B
Verandering (1 dag)
1.76%
Verandering (1 jaar)
131.10%
Land
US
Handel Glaukos Corporation (GKOS)

Categorie

Healthcare
Koersgeschiedenis voor Glaukos Corporation (GKOS)
Hoogste slotkoers: $166.80 op 2026-10-01

Laagste slotkoers: $29.05 op 2015-06-01
Koersgeschiedenis van Glaukos Corporation van 2015 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2026 (TTM) 16.37%
2025 -22.38%
2024 97.91%
2023 64.84%
2022 1.09%
2021 -38.87%
2020 24.29%
2019 -5.51%
2018 133.10%
2017 -22.73%
2016 38.93%
2015 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$100.56 -21.41%
US
$93.07 -2.95%
IE
$297.13 -23.49%
US
$44.47 -57.18%
US
$46.87 -18.19%
DE